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Purpose: Anti-vascular endothelial growth factor (VEGF) agents have recently been used intravitreally during the
perioperative period for proliferative diabetic retinopathy (PDR). However, the mechanism of theraputic effects of the
agents remains unclear. This study aimed to investigate the effects of intravitreal bevacizumab (IVB) on retinal vascular
endothelial cells and expressions of VEGF and hypoxia inducible factor-1α (HIF-1α) in PDR.
Methods: Twenty-four patients with PDR were enrolled and randomized to two groups. Twelve eyes of 12 patients of
each group received either an intravitreal injection of 1.25 mg bevacizumab or a sham injection 6 days before vitrectomy.
Neovascular membranes (NVMs) were collected during pars plana vitrectomy. The numbers of vascular endothelial cells
in the NVMs were counted after staining with hematoxylin and eosin and von Willebrand. The expressions of VEGF and
HIF-1α in the NVMs were detected through immunohistochemistry. Ten epiretinal membrane specimens from patients
with proliferative vitreoretinopathy (PVR) without IVB treatment were set as an additional control.
Results: The number of vascular endothelial cells in NVMs of the IVB pretreated group was significantly lower than that
of the sham group (21.5±3.94 versus 41.33±7.44, p=0.003). The IVB pretreated group also showed significantly lower
levels of VEGF and HIF-1α in NVMs than those of the sham group (PHIF-1α=0.02, PVEGF<0.001). A stepwise regression
analysis showed that IVB was a significant negative predictor for the numbers of vascular endothelial cells (β=–0.89,
p<0.001) and the expressions of VEGF (β=–0.85, p<0.001) and HIF-1α (β=–0.64, p=0.001) in PDR patients. Epiretinal
membranes of the PVR group showed negative staining of VEGF and HIF-1α.
Conclusions:  Pretreatment  with  IVB  in  patients  with  PDR  significantly  decreased  vascular  endothelial  cells  and
expressions of VEGF and HIF-1α, which further supports preoperative use of IVB in such patients.
Diabetic retinopathy (DR) is the leading cause of vision
loss in the working-age population worldwide [1]. There is a
reported 37% prevalence of DR among patients with diabetes
and 54% after 10–19 years with diabetes [2]. Proliferative
diabetic retinopathy (PDR) indicates occurrence of retinal
neovascularization  (RNV)  and  subsequent  serum  leakage,
hemorrhage, and fibrovascular proliferation in the vitreous–
retinal  interface,  which  further  results  in  macular  edema,
vitreous hemorrhage, and traction retinal detachment. Severe
vision is inevitable when RNV occurs.
Vascular  endothelial  growth  factor  (VEGF)  is  an
essential growth factor for angiogenesis and is particularly
regulated  by  hypoxia  inducible  factor-1α  (HIF-1α)  under
hypoxic  conditions  [3,4].  Increased  levels  of  VEGF  and
HIF-1α  were  detected  in  the  vitreous  humor  and  in
fibrovascular tissues from eyes with PDR [5–10]. VEGF and
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HIF-1α  were  indicated  to  provide  targets  for  therapeutic
intervention on RNV [11].
Pegaptanib  and  ranibizumab,  two  medicines  for  anti-
VEGF, have been in use for the treatment of neovascular age-
related macular degeneration since 2006 [12]. Bevacizumab
(Avastin) is a human-derived full-length monoclonal antibody
binding all isoforms of VEGF [13]; it is approved for use in
the United States as an anti-angiogenic agent for metastatic
colorectal  cancer  [14].  However,  intravitreal  injection  of
bevacizumab (IVB) as an off-label application has also been
successfully used for the treatment of various types of ocular
neovascularization,  including  RNV,  choroidal
neovascularization,  and  neovascular  glaucoma.  Several
independent lines of studies have corroborated encouraging
findings in IVB therapy for DR with macular edema and RNV
(including perioperative use) [15].
Although the overwhelming evidence in clinical trials
supports further investigation of IVB for PDR, there is little
information on histopathology, especially of the effects of
IVB on neovascular membranes (NVMs) of PDR. This study
aimed  to  examine  the  effects  of  IVB  on  retinal  vascular
endothelial cells and expressions of VEGF and HIF-1α via
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2immunostaining of NVMs surgically removed from eyes of
patients with PDR.
METHODS
Patients and materials: Patients with PDR were recruited
from  August  2008  to  January  2009  in  our  department
(Department  of  Ophthalmology,  Xijing  Hospital,  Xi’an,
Shaanxi,  China).  The  patients  all  had  active  NVMs  and
associated  complications,  including  vitreous  hemorrhage,
partial traction retinal detachment, and macular edema with
visual  acuity  less  than  0.1  (Table  1).  No  patient  had  iris
neovascularization. All patients were indicated for vitrectomy
treatment. Patients with cerebrovascular accident, myocardial
infarction, deep venous thrombosis, and uncontrolled arterial
hypertension  and  other  eyes  diseases  were  excluded.  The
study protocol was reviewed and approved by the Fourth
Military  Medical  University  Medical  Ethics  Committee
(Xijing Hospital Medical Ethics No. 402). Written informed
consent was obtained from all eligible patients in compliance
with the Declaration of Helsinki for research involving human
subjects. In total, 24 patients (24 eyes) were enrolled. None
of  the  patients  had  received  pan  retinal  photocoagulation
(RPR),  but  seven  patients  (No.  4,  8,  and  10  in  the  IVB
pretreated group and No. 2, 9, 23, and 24 in the sham group)
had received one session of scant retinal photocoagulation
with laser spots less than 500 before admission. Patients were
randomized in two groups of 12 each. One group was the IVB
pretreated  group  with  intravitreal  injection  of  1.25  mg
bevacizumab (Avastin; Genentech, Inc., South San Francisco,
CA), while the second group was the sham group with a sham
injection 6 days before surgery. Ten nondiabetic patients (10
eyes) with rhegmatogenous retinal detachment complicated
with  proliferative  vitreoretinopathy  (PVR)  received
vitrectomy,  and  the  epiretinal  membranes  were  collected
during vitrectomy and set as additional controls.
Specimens: The NVMs were surgically removed from each
eye  during  pars  plana  vitrectomy  and  preserved  in  4%
polyoxymethylene solution for 24 h. Following dehydration
in  graded  ethanol,  cleared  in  xylene,  and  embedded  in
paraffin, each specimen was serially cut into 3-μm thick slices.
Slides were deparaffinized, rehydrated through a graded series
of ethanol, and rinsed in distilled water. Hematoxylin and
eosin  staining  and  von  Willebrand  (BioLegend  Inc.,  San
Diego, CA) staining were employed for vascular endothelial
cell counting in NVM sections.
Vascular  endothelial  cell  counting::  For  each  NVM
specimen,  20  consecutive  slides  were  examined  with  an
inverted  phase-contrast  microscope  (Carl  Zeiss  AG.
Oberkochen, Germany). Five visual fields (N1–N5) of each
slide were chosen for analysis. Images were captured at a
magnification  of  200×.  Results  were  recorded  as  mean  ±
standard deviation (SD).
Immunohistochemistry:  Immunohistochemical  staining  for
detection of VEGF and HIF-1α expressions was done using a
three-step immunoperoxidase method (labeled streptavidin
biotin)  as  follows.  Twenty  consecutive  slides  of  each
specimen  were  incubated  with  3%  hydrogen  peroxide  to
quench endogenous peroxidase. Microwave antigen retrieval
was performed in citrate buffer (0.01 mol/l; pH=6.0) for 1.5
min.  The  sections  were  blocked  with  normal  goat  serum
(Vector Laboratories Inc. Burlingame, CA) for 30 min at room
temperature and then incubated with the primary antibody at
4  °C  in  humid  chambers  overnight.  For  determining
expressions  of  VEGF  and  HIF-1α  in  specimens,  rabbit
polyclonal  anti-VEGF  antibody  (1:100;  Abcam  Plc.,
Cambridge,  UK)  and  mouse  monoclonal  anti-HIF-1α
antibody (1:100; Abcam) were used as the primary antibody,
respectively. After rinsing in PBS (0.01 mol/l, pH=7.2, NaCl
8.0 g, KCl 0.2 g, Na2HPO4 1.44 g, KH2PO4 0.24 g, solved in
1,000 ml distilled water) and incubating with a biotinylated
secondary antibody (1:2,000; Vector Laboratories) for 30 min
at 37 °C, the sections were then treated with streptavidin
horseradish peroxidase (Vector Laboratories) for 30 min at
37 °C. Antigens were visualized with a diaminobenzidine kit
(Sigma,  St.  Louis,  MO).  All  sections  were  observed  in  a
bright-field  microscope  (Olympus,  Tokyo,  Japan)  and
analyzed with ImagePro-Plus (Media Cybernetics, Bethesda,
TABLE 2. THE CLINICAL CHARACTER OF THE INTRAVITREAL BEVACIZUMAB (IVB) PRETREATED GROUP AND SHAM TREAT GROUP WERE
COMPARABLE.
Clinical character IVB treated (n=12) sham (n=12) p value
Male (%) ‡ 50.00%   41.67% 0.69
Age (Year)† 50.33±7.60   53.25±5.14 0.28
Duration of DR (Month)† 11.50±7.75   18.41±11.90 0.11
Duration of Diabetes (Year)† 11.92±6.02   17.17±3.86 0.02*
Vision (LogMAR) ‡ 1.93±0.47   2.16±0.47 0.21
        Gender, age, duration of diabetic retinopathy, and vision distribution of patients in the two groups had no significant difference.
        Duration of diabetes in the sham group was significantly longer (* p<0.05) than that of the IVB treat group. IVB=intravitreal
        becacizumab.  All  data  are  represented  by  mean±SD,  except  for  those  representing  percent  (%),  †  Student’s  t-test,  ‡:
        NonParametric test (Mann–Whitney test).
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3Figure 1. Pretreatment with intravitreal bevacizumab (IVB) significantly reduced the numbers of vascular endothelial cells in neovascular
membranes (NVMs) of the eyes with proliferative  diabetic retinopathy  (PDR).  Hematoxylin  and  eosin  stain  (H&E; A, C, and E) and von
Willebrand stain (B, D, and F) were  applied  to  detect  the vascular endothelial cells in the NVMs  of PDR eyes  (A-D)  and epiretinal mem-
branes  of  the  eyes  with  proliferative  vitreoretinopathy  (PVR; E, F).  The untreated  group  (A, B) shows a significantly more number of
vascular endothelial cells when compared to the IVB pretreated group (C, D; p=0.003).  The epiretinal  membranes of PVR eyes were set as
the control group.  von Willebrand stain for vascular endothelial cells in the  control  group was negative (F).  Figures were selected as
representative data from three independent experiments. Scale bars: 200 μm.
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4MD) software [16,17]. The results of average optical density
(AOD) were recorded as mean±SD.
Negative controls were performed with normal rabbit
serum  diluted  to  the  same  concentration  as  the  primary
antibody, PBS in substitution of the primary antibody was
used as blank control.
Statistics  analysis:  The  Student  t  test,  nonparametric  test
(Mann–Whitney test), and stepwise regression analysis were
applied to determine the difference between the two groups.
A level of significance was set at p<0.05.
RESULTS
In the present study, we hypothesized that pretreatment with
intravitreal injection of bevacizumab in PDR patients before
vitrectomy can significantly decrease the amount of vascular
endothelial cells and expressions of VEGF and HIF-1α in the
neovascular membranes.
Patient demography data: The patient demography data
are summarized in Table 1. All eyes with PDR were classified
as stage 5 according to the International Clinical Diabetic
Retinopathy  Disease  Severity  Scale  [18].  Thirteen  of  24
(54.1%) patients had a history of insulin therapy. The others
(45.9%) took oral hypoglycemic drugs for control of blood
glucose level. The best corrected visual acuity before surgery
ranged from light perception to 0.06. No significant difference
was found in the gender (p=0.69), age (p=0.28), preoperative
vision (p=0.21), and duration of DR (p=0.11) between IVB
pretreated and sham groups. The history of diabetes of the IVB
pretreated group (11.92±6.02 years; range, 1–20 years) was
significantly shorter than that of the sham group (17.17±3.86
years; range, 10–23 years; p=0.02; Table 2).
Vascular endothelial cell counting: Compared with the
IVB pretreated group, more endothelial cells were found in
the  sham  group  (21.50±3.94  versus  41.33±7.44,  p=0.003;
Figure 1 and Figure 2). No endothelial cells were found in
epiretinal membranes of the PVR control group. A stepwise
regression  analysis  showed  that  IVB  was  a  significant
negative predictor for the number of vascular endothelial cells
(β=–0.89, p<0.001).
Expressions  of  vascular  endothelial  growth  factor
(VEGF)  and  hypoxia  inducible  factor-1alpha  (HIF-1α):
Positive staining of VEGF and HIF-1α were found in the
cytoplasm  of  the  endothelial  cells  in  all  NVM  sections.
Immunoreactivity intensity of HIF-1α and VEGF in the NVM
sections in the IVB pretreated group were significantly lower
than that of the sham group (PHIF-1α=0.02, PVEGF < 0.001). The
AOD values of VEGF and HIF-1α proteins of the two groups
were 58.66±3.21 versus 80.08±3.01 and 82.25±14.18 versus
97.91±16.94, respectively. Epiretinal membranes of the PVR
control group showed negative staining (Figure 3 and Figure
4). A stepwise regression analysis indicated that IVB was a
significant negative predictor for the expressions of VEGF
(β=–0.85, p<0.001) and HIF-1α (β=–0.64, p=0.001).
DISCUSSION
DR was preliminarily treated by pan retinal photocoagulation
(PRP) in 1970s [19], and it was reported to reduce the risk of
Figure 2. Increased vascular endothelial
cell  count  in  eyes  with  proliferative
diabetic  retinopathy  (PDR)  was
suppressed  by  pretreatment  of
intravitreal  bevacizumab  (IVB).  The
epiretinal  membranes  of  proliferative
vitreoretinopathy (PVR) eyes were set
as  the  control  group.  Quantitative
analysis for the vascular endothelial cell
count  in  the  neovascular  membranes
(NVMs)  of  PDR  eyes  and  epiretinal
membranes  of  PVR  eyes  was
determined  by  counting  positively
stained cells in 10 representative fields.
Each  value  represents  means±SEM
from  three  independent  experiments
(p=0.003).
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5severe vision loss by 50% [20,21]. VEGF plays a central role
in  ocular  neovascularization  [22].  One  mechanism  of
panretinal photocoagulation on the regression of NVM is the
inhibition of VEGF production [23]. However, breakup does
not  occur  until  clinical  application  of  anti-VEGF  agents,
including pegaptanib, bevacizumab, and ranibizumab. In the
recent years, intravitreal injection of anti-VEGF agents has
emerged as the most advanced treatment of the devastating
diabetic complications. These drugs directly neutralize the
function of VEGF. Current studies have shown that patients
can benefit more from anti-VEGF therapy than panretinal
photocogulation, such as less intervention by opacified media
and concurrent macular edema. In addition, preoperative IVB
injections in PDR may lessen the bleeding during an operation
and decrease the occurrence of complications and repeated
surgery,  which  improves  the  anatomic  and  functional
recovery [24]. Avery et al. [25] reported a dramatic and rapid
involution of retinal (73%) and iris (82%) neovascularization
secondary  to  PDR  after  a  single  intravitreal  injection  of
bevacizumab. Spaide et al. [26] showed that there was rapid
resolution of vitreous hemorrhage and RNV regression in two
patients with PDR after intravitreal bevacizumab within 1
month. Arevalo et al. .  [27]      reported     t  hat,   after treatment  with
IVB  for  patients  with  PDR,  61.4%  patients  showed  total
regression of RNV, 34.1% patients showed partial regression
of RNV, and ETDRS best corrected visual acuity testing and
optical  coherence  tomography  demonstrated  significant
improvement after an average of 28.4 weeks follow up (range,
24–40 weeks). Erdol et al. [28] reported that, after   a   single
dose  of  bevacizumab,  complete  resolution  of
Figure 3. Pretreatment of intravitreal bevacizumab (IVB) remarkably reduced the levels of hypoxia inducible factor-1 alpha (HIF-1α) and
vascular endothelial growth factor (VEGF) in eyes with proliferative diabetic retinopathy (PDR). Immunohistochemistry for HIF-1α (A, C)
and VEGF (B, D) was performed in the neovascular membranes (NVMs) of no IVB pretreated sham group (A, B) and IVB pretreated group
(C, D). The stain of both HIF-1α and VEGF in the IVB pretreated group (C, D) was significantly lower than that of the no IVB pretreated
sham group (A, B). Figures were selected as representative data from three independent experiments. Scale bars: 200 μm.
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6neovascularization was 78.8% at 1 month, 63.6% at 3 months,
and 45.4% at 6 months.
However, the molecular and pathological mechanism of
IVB  on  PDR  is  unclear.  In  this  study  we  observed  that
pretreatment with IVB predominantly decreased amounts of
vascular endothelial cells in NVM, which is consistent with
previous clinical trials [25–28]. Meanwhile, we found that the
IVB-pretreated group also showed significantly lower levels
of VEGF and HIF-1α in NVMs than the non-IVB-pretreated
group. Our results are compatible with a recent study that the
numbers  of  VEGF-positive  vascular  endothelial  cells
significantly decreased in the fibrovascular membranes of
patients with PDR after intravitreal injection of bevacizumab
[29]. HIF-1 and VEGF have been suggested to be involved
[4] in angiogenesis of PDR membranes since HIF-1 mediates
the  angiogenic  response  to  hypoxia  by  upregulating  the
expression  of  multiple  angiogenic  cytokines  and  VEGF
directly  promotes  vascular  endothelial  cell  proliferation,
migration,  and  tube  formation.  Abu  El-Asrar  et  al.  [8]
demonstrated that significantly increased intensity of HIF-1
immunoreactivity  is  concomitant  with  higher  angiogenic
activity in epiretinal membranes. Our results suggested that
IVB  pretreatment  decrease  the  vascular  endothelial  cell
number through down regulation of the expressions of HIF-1
and VEGF in PDR eyes.
Kohno et al. [30] found that IVB is effective in PDR and
neovascular  glaucoma,  which  leads  to  endothelial  cell
apoptosis  with  vascular  regression.  Studies  showed  that
VEGF can inhibit endothelial cell apoptosis through protein
kinase B (Akt/PKB) signaling pathway. While in Pattwell et
al. [31] study of 6 PDR membranes with IVB pretreatment,
histologically detectable capillaries was found in 3 clinically
avascular membranes, “ghost” vessels were found in one, and
the  other  two  were  both  clinically  and  histologically  still
vascularized. They suggested a vaso-constrictive rather than
vaso-obliterative response occurred after IVB treatment for
PDR.  Our  study  showed  that  the  numbers  of  vascular
endothelial cells in the NVM of PDR patients pretreated with
IVB significantly decreased but were not totally eliminated.
Our results are compatible with the study of Kubota et  al.
[29] that vascular endothelial cells with decreased expression
of VEGF are still present in the NVM of PDR after IVB.
In  our  study  four  patients  with  IVB  pretreatment
(33.33%) had transient ocular hypertension (22–26 mmHg)
after surgery. No other complication was noted. The Pan-
American Collaborative Retina Study Group [32] studied the
safety  of  IVB  and  followed  up  for  12  months.  Repeated
intravitreal  injections  of  either  1.25  mg  or  2.50  mg  of
bevacizumab appeared to be safe and well tolerated during the
first year [32]. Systemic adverse events were reported in 18
(1.50%) patients, including seven cases (0.59%) of an acute
Figure  4.  Pretreatment  of  intravitreal
bevacizumab  (IVB)  remarkably
reduced  the  expressions  of  hypoxia
inducible factor-1 alpha (HIF-1α) and
vascular  endothelial  growth  factor
(VEGF)  in  eyes  with  proliferative
diabetic  retinopathy  (PDR).
Quantitative analysis for the levels of
HIF-1α and VEGF in the PDR eyes was
measured  by  measuring  the  Average
Optic  Density  values  of  each  image
using  ImagePro-Plus  (Media
Cybernetics) software. The expression
levels  of  both  HIF-1α  (p=0.02)  and
VEGF (p<0.001) in the IVB pretreated
group was significantly lower than those
of the no IVB treated group. Each value
represents  means±SEM  from  three
independent experiments (n=12).
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7elevation  of  blood  pressure,  six  cases  of  cerebrovascular
accident (0.50%), five cases of myocardial infarction (0.40%),
two cases of iliac artery aneurysm (0.17%), two cases of toe
amputation (0.17%), and five cases of death (0.40%) [32].
Ocular  complications  included  seven  cases  (0.16%)  of
bacterial endophthalmitis, seven cases (0.16%) of traction
retinal detachments, four cases (0.09%) of uveitis, one case
(0.02%) of rhegmatogenous retinal detachment, and one case
(0.02%) of vitreous hemorrhage [32].
Our study compared the histology of the fibrovascular
membranes in PDR with or without IVB. Although the study
was not a pre and post self-control study of the same specimen,
the  inter-group  differences  were  limited.  There  were  no
significant differences in gender, age, duration of DR, or best
corrected visual acuity between the two groups except for the
duration of diabetes. The history of diabetes of the IVB group
was significantly shorter than that of the group without IVB.
Some  patients  ignored  the  disease  in  the  early  stages  of
diabetes, for example, two patients of the IVB group did not
go to the hospital until they had gradually lost vision. By then,
the diabetic retinopathy had developed to stage V and they
were diagnosed to have type 2 diabetes mellitus. We therefore
assume that the duration of diabetes in some patients is not
actually the duration of disease, which is probably one of the
reasons for the differences between the two groups. Several
patients (three in the IVB pretreated group and four in the
sham  group)  received  one  session  of  scant  retinal
photocoagulation with less than 500 spots; however, we did
not considered this to be sufficient to impact the progression
of PDR. Meanwhile the severity of PDR of the two groups
was consistent, including the NVM, vitreous hemorrhage,
macular  edema,  and  limited  traction  retinal  detachment
without  iris  neovascularization.  In  addition,  stepwise
regression  analysis  showed  that  IVB  was  a  significant
negative predictor for amounts of vascular endothelial cells
and expressions of VEGF and HIF-1α.
In conclusion, our study demonstrated that pretreatment
with IVB in PDR patients significantly decreases amounts of
vascular  endothelial  cells  and  expressions  of  VEGF  and
HIF-1α. This yields further support for the preoperative use
of IVB in such patients from a histopathological point of view.
Despite our sample size being small and the results limited,
our findings provide additional information for clinical trials
of IVB treatment for PDR. Further investigations involving a
larger group with appropriate randomization and a control
group will be necessary to confirm our preliminary findings.
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